Adicet Bio, Inc.
ACETHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The $89.8M market capitalization puts ACET squarely in micro-cap range for its industry. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Market Cap
$89.8M
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
-2.37
EPS (TTM)
$-10.42
EPS (Fwd)
$-4.04
ROE
-78.1%
ROA
-41.7%
Cash
$118.2M
Total Debt
$12.9M
Free CF
-$47.5M
52W Change
-25.4%
Annual Financials
Cash vs Debt
Where ACET stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ACET finished 16.92% above its 150-day moving average ($7.92) and 14.75% above its 200-day moving average ($8.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACET overbought or oversold?
At the September 3, 2026 close, ACET's RSI(14) was 66.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $118.2M in cash and $12.9M in debt, ACET maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$47.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -78.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $9.7M (2021) to $0 (2025), a 100% decline worth watching.
Adicet Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ACET has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACET.